Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Generalized Myasthenia Gravis Patients with oculobulbar, bulbar or generalized MG ≥ 18 years of age and with onset of generalized symptoms or neurophysiological detection of generalized disease not more than 12 months ago. 2. The diagnosis of MG should be determined with the following: Clinical neurological status with motor symptoms consistent with MG and at least two of the following: a positive serologic test for anti-acetylcholine receptor antibody (AChR) and/or b. typical MG findings on neurophysiological testing of neuromuscular transmission with single fiber electromyography (SFEMG) and / or repetitive nerve stimulation (RNS), and / or c. Positive anti-choline esterase-test, e.g. edrophoniumchloride or improvement of MG symptoms with oral cholinesterase inhibitors as judged by the treating physician. 3. MGFA Class II to IV at screening. 4. Quantitative MG score ≥ 6 at screening 5. Women of childbearing potential must have a negative pregnancy test. 6. Patients must have provided written informed consent. 7. Patients must be able and willing to comply with all study procedures  Weakness only affecting ocular or periocular muscles (MGFA Class I). 2. MG crisis at screening (MGFA Class V) 3. Thymectomy already carried out. In order to avoid difficulties to evaluate the effect of the study drug, thymectomy, where it is indicated, should be scheduled to the follow-up period, ie after the first 24 weeks. 4. Strong suspicion of thymoma, where thymectomy as judged by the treating physician should be done within 24 weeks. 5. Active malignancy, if not adequately treated 6. Pregnancy or breast-feeding. 7. Ongoing acute or chronic viral or systemic bacterial infections including HIV, latent hepatitis B, which is clinically significant, according to the study doctor's opinion and not treated with appropriate antibiotic / antiviral drugs. 8. Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease 9. Previous use of immunosuppressive drugs, including rituximab, except prednisolone at a dose of up to 40mg daily for less than 3 months. This does not apply to treatment with immunosuppressive drugs / corticosteroids (except rituximab) for other indications than MG, provided at least 12 months have passed since treatment was terminated. 10. Suspected hypersensitivity to the study drug 11. Participation in another trial of study drug within 30 days prior to screening. 12. Any medical condition which, according to the study physician's opinion, may interfere with the patient's participation in the study, poses additional risks for the patient, or that complicate the assessment of patients. 13. Vaccination within 4 weeks before inclusion